News
Biodexa has enrolled the initial two subjects in the Phase III Serenta study of eRapa, involving individuals with FAP.
Anocca has secured approximately Skr440m (around $46m) to primarily support the early-stage clinical trials of VIDAR-1.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback